C4 Therapeutics, Roche expand partnership with new cancer deal worth over $1 billion

ReutersApr 9, 2026 1:20 PM

April 9 (Reuters) - C4 Therapeutics CCCC.O said on Thursday it has entered into a deal focused on research and development of a type of cancer drug with Swiss drugmaker Roche ROPC.S that could be worth more than $1 billion.

The companies will collaborate on two programs to develop degrader-antibody conjugates against undisclosed oncology targets exclusive to the agreement.
Degrader-antibody conjugates (DAC) are an emerging class of cancer therapies that combine antibody-drug conjugation with targeted protein degradation technology.
Roche will be responsible for advancing DAC candidates through preclinical and clinical development as well as commercialization.
C4T will receive a $20 million upfront payment for the two programs. If Roche exercises its option for a third target, C4T will receive an additional payment.
C4T is also eligible to receive over $1 billion in discovery, regulatory and commercial milestone payments, and entitled to tiered royalties on future sales.
The agreement marks the third collaboration between the two companies and extends a relationship that began in 2016.

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Recommended Articles

Nvidia Releases Open-Source Quantum AI Model Ising, Quantum Computing Sector Rises Collectively, IonQ Gains Over 20%

TradingKey - On April 14, 2026, local time, NVIDIA (NVDA) officially released NVIDIA Ising, an open-source quantum AI model licensed under Apache-2.0. The model focuses on two core engineering challenges: quantum processor calibration and quantum error correction.

Micron Surges 9% to Record High as Nasdaq Hits 10-Day Winning Streak: Will Memory Stocks Lead the Bull Market’s Return?

TradingKey - At the U.S. market close on April 14, the Nasdaq completed a 10-day winning streak, marking its longest since 2021; NVIDIA (NVDA) , AMD also recorded 10-day winning streaks. Micron (MU) surged 9% to a new closing high, leading the U.S. chip sector. The Philadelphia Semiconductor Index r

Anthropic IPO vs OpenAI IPO: Can an $800 Billion Valuation Help Anthropic Claim the First Large Model Stock?

TradingKey – An $800 billion valuation for Anthropic: this is the most staggering figure in the global AI investment circle as of April 2026. According to Business Insider, several venture capital firms have proactively extended investment offers to Claude developer Anthropic, with valuations reaching up to $800 billion—double the $380 billion valuation from its Series G round just two months prior. Notably, Anthropic has yet to accept any new funding, despite Silicon Valley capital vying for a stake. With the company set to launch its IPO as early as October 2026, the battle for the title of "the first public LLM stock" between the Anthropic IPO and the OpenAI IPO has officially begun.

Software Stocks Are Continuing to Rebound, Should Investors Buy Oracle or Microsoft Now?

TradingKey - Following a 12.7% single-day surge in Oracle's (ORCL.US) share price on April 13, which added $50.4 billion to its market capitalization, the stock extended its rally on April 14, rising another 4.74% to $163, as trading volume expanded to $9.783 billion.

ASML 2026 Q1 Earnings Preview: Valuations Are Already at Highs, Can AI Orders Support Growth Expectations?

TradingKey - Global lithography leader ASML is set to disclose its first-quarter 2026 financial results on April 15. Market focus on the company's short-term performance volatility and long-term growth potential continues to intensify.

Featured Tools